SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-015384
Filing Date
2019-05-02
Accepted
2019-05-02 17:00:59
Documents
63
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 Q119 10-Q ntla-10q_20190331.htm 10-Q 1884855
2 EX-10.1 ntla-ex101_195.htm EX-10.1 40119
3 EX-31.1 ntla-ex311_7.htm EX-31.1 17027
4 EX-31.2 ntla-ex312_8.htm EX-31.2 17043
5 EX-32.1 ntla-ex321_6.htm EX-32.1 6272
6 GRAPHIC gajot0tkw1qu000001.jpg GRAPHIC 76324
  Complete submission text file 0001564590-19-015384.txt   7753628

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT ntla-20190331.xml EX-101.INS 1925087
8 XBRL TAXONOMY EXTENSION SCHEMA ntla-20190331.xsd EX-101.SCH 50596
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20190331_cal.xml EX-101.CAL 42755
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20190331_def.xml EX-101.DEF 140996
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20190331_lab.xml EX-101.LAB 392915
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20190331_pre.xml EX-101.PRE 281598
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 19792807
SIC: 2835 In Vitro & In Vivo Diagnostic Substances